Mirum Pharmaceuticals, Inc.

This study tests a new medicine called BJT-778 for people with chronic hepatitis delta, a serious liver infection. About 150 adults will either start the drug right away or wait 24 weeks before starting it. The goal is to see if the drug can lower virus levels and improve liver h…

This study tests a drug called volixibat to see if it can reduce severe itching caused by primary sclerosing cholangitis (PSC), a rare liver disease. About 182 people aged 12 and older with PSC-related itching will receive either volixibat or a placebo. The main goal is to measur…

This study tests if maralixibat can safely reduce severe itching in children and adults with rare cholestatic liver diseases who have not responded to other treatments. Participants receive either the drug or a placebo, and researchers measure changes in itch severity and bile ac…